How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?

Finerenone has a different mechanism of action from SGLT2 inhibitors and may have a synergistic effect when used in combination with other GDMT medications as a replacement for eplenerone or spironolactone, with a lower risk of progressive kidney disease. Similar to other MRAs, patients should be mo...

Finerenone could replace spironolactone or eplerenone since the likelihood of adverse effects are less. Unfortunately, RCTs of finerenone have compared it placebo. Until superiority to spironolactone (a cheap and very effective drug for heart failure) is shown we cannot justify the cost.